This company has been marked as potentially delisted and may not be actively trading. Zafgen (ZFGN) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ZFGN vs. ARCT, CKPT, PHAT, OLMA, TRDA, ALT, BNTC, MREO, RNAC, and MBXShould you be buying Zafgen stock or one of its competitors? The main competitors of Zafgen include Arcturus Therapeutics (ARCT), Checkpoint Therapeutics (CKPT), Phathom Pharmaceuticals (PHAT), Olema Pharmaceuticals (OLMA), Entrada Therapeutics (TRDA), Altimmune (ALT), Benitec Biopharma (BNTC), Mereo BioPharma Group (MREO), Cartesian Therapeutics (RNAC), and MBX Biosciences (MBX). These companies are all part of the "medical" sector. Zafgen vs. Arcturus Therapeutics Checkpoint Therapeutics Phathom Pharmaceuticals Olema Pharmaceuticals Entrada Therapeutics Altimmune Benitec Biopharma Mereo BioPharma Group Cartesian Therapeutics MBX Biosciences Zafgen (NASDAQ:ZFGN) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, community ranking, valuation, analyst recommendations, media sentiment and institutional ownership. Which has more risk & volatility, ZFGN or ARCT? Zafgen has a beta of 0.27, meaning that its share price is 73% less volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 3.41, meaning that its share price is 241% more volatile than the S&P 500. Is ZFGN or ARCT more profitable? Zafgen has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -36.39%. Arcturus Therapeutics' return on equity of -22.39% beat Zafgen's return on equity.Company Net Margins Return on Equity Return on Assets ZafgenN/A -51.34% -34.55% Arcturus Therapeutics -36.39%-22.39%-14.81% Does the MarketBeat Community prefer ZFGN or ARCT? Arcturus Therapeutics received 102 more outperform votes than Zafgen when rated by MarketBeat users. However, 68.59% of users gave Zafgen an outperform vote while only 66.32% of users gave Arcturus Therapeutics an outperform vote. CompanyUnderperformOutperformZafgenOutperform Votes34568.59% Underperform Votes15831.41% Arcturus TherapeuticsOutperform Votes44766.32% Underperform Votes22733.68% Do analysts recommend ZFGN or ARCT? Arcturus Therapeutics has a consensus target price of $59.20, suggesting a potential upside of 361.42%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcturus Therapeutics is more favorable than Zafgen.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zafgen 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Arcturus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13 Which has better valuation & earnings, ZFGN or ARCT? Arcturus Therapeutics has higher revenue and earnings than Zafgen. Arcturus Therapeutics is trading at a lower price-to-earnings ratio than Zafgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZafgenN/AN/A-$45.41M-$1.07-2.78Arcturus Therapeutics$138.39M2.51-$29.73M-$3.01-4.26 Does the media favor ZFGN or ARCT? In the previous week, Arcturus Therapeutics had 4 more articles in the media than Zafgen. MarketBeat recorded 4 mentions for Arcturus Therapeutics and 0 mentions for Zafgen. Arcturus Therapeutics' average media sentiment score of 1.47 beat Zafgen's score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Zafgen Neutral Arcturus Therapeutics Positive Do institutionals and insiders hold more shares of ZFGN or ARCT? 70.4% of Zafgen shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 14.2% of Zafgen shares are owned by insiders. Comparatively, 15.3% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. SummaryArcturus Therapeutics beats Zafgen on 14 of the 18 factors compared between the two stocks. Get Zafgen News Delivered to You Automatically Sign up to receive the latest news and ratings for ZFGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZFGN vs. The Competition Export to ExcelMetricZafgenPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$111.29M$6.86B$5.56B$8.03BDividend YieldN/A2.90%5.36%4.23%P/E Ratio-3.097.5422.8118.89Price / SalesN/A259.70406.35106.96Price / CashN/A65.8538.1834.62Price / Book2.206.566.794.34Net Income-$45.41M$143.88M$3.23B$248.27M Zafgen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZFGNZafgenN/A$2.97+3.8%N/A-61.8%$111.29MN/A-3.0938High Trading VolumeARCTArcturus Therapeutics3.0093 of 5 stars$12.82-0.7%$59.20+361.8%-53.0%$347.68M$138.39M-5.77180News CoveragePositive NewsCKPTCheckpoint Therapeutics2.3322 of 5 stars$4.11+0.2%$4.33+5.4%+160.8%$344.27M$41,000.00-2.2310Upcoming EarningsNews CoveragePositive NewsPHATPhathom Pharmaceuticals3.7628 of 5 stars$4.15+1.0%$21.83+426.1%-72.5%$339.88M$55.25M-0.73110Analyst ForecastNews CoverageOLMAOlema Pharmaceuticals2.5101 of 5 stars$4.89-0.4%$27.67+465.8%-47.3%$334.15MN/A-2.2370Upcoming EarningsNews CoverageTRDAEntrada Therapeutics3.001 of 5 stars$8.87+0.3%$25.67+189.4%-29.9%$333.47M$210.78M5.58110Upcoming EarningsNews CoverageALTAltimmune2.4147 of 5 stars$5.06-0.2%$20.83+311.7%-21.0%$326.54M$20,000.00-3.2650Upcoming EarningsNews CoverageBNTCBenitec Biopharma2.7473 of 5 stars$13.64+0.4%$24.71+81.2%+68.2%$319.87M$80,000.00-9.0320News CoveragePositive NewsMREOMereo BioPharma Group2.3554 of 5 stars$2.61+4.4%$7.71+195.6%-18.1%$316.41M$1M-43.5040News CoveragePositive NewsRNACCartesian Therapeutics1.9843 of 5 stars$12.21+3.2%$42.67+249.4%-50.4%$316.32M$38.91M-0.2364Upcoming EarningsMBXMBX Biosciences2.6637 of 5 stars$9.35+2.0%$37.50+301.1%N/A$312.51MN/A0.0036Positive News Related Companies and Tools Related Companies ARCT Alternatives CKPT Alternatives PHAT Alternatives OLMA Alternatives TRDA Alternatives ALT Alternatives BNTC Alternatives MREO Alternatives RNAC Alternatives MBX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZFGN) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredDonald Trump is about to free crypto from its chains …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zafgen Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Zafgen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ZFGN Stock Free ZFGN Stock Alerts